Home / Conditions / Benzodiazepine Use Disorder
Benzodiazepine Use Disorder: when insurers say no, reviewers often say yes
In 23 published external-review decisions involving benzodiazepine use disorder, independent physician reviewers overturned the insurer’s denial 82.6% of the time.
Published decisions
23
2001–2026
Overturned
82.6%
19 denials reversed
Most-fought treatments for benzodiazepine use disorder
What insurers denied — and how those fights ended.
| Treatment | Decisions | Overturned |
|---|---|---|
| Residential Treatment Center | 22 | 81.8% |
Typical time to a decision
17 days
Most land between 8 and 21 days
Handled as urgent
43.5%
Expedited when a delay would cause harm
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested reimbursement and prospective authorization and coverage for residential treatment center (RTC) services (ASAM 3.1). Per the American Society of Addiction Medicine (ASAM) criteria, this patient meets Level 3.1 criteria for RTC services for the time period under review. ASAM criteria focuses on six dimensions to determine the appropriate level of care, which includes: (1) intoxication and associated risk, withdrawal and associated risks, and addiction medication needs; (2) biomedical conditions including physical health concerns and pregnancy-related concerns; (3) psychiatric and cognitive conditions and history including active psychiatric symptoms and persistent disability; (4) substance use-related risks including the likelihood of engaging in risky substance use and the likel…
Nature of Statutory Criteria/Case Summary: The patient has requested reimbursement and prospective authorization and coverage for residential treatment center (RTC) services (ASAM 3.1). For Dimension 1 The patient’s urine toxicology on admission was positive for amphetamine, benzodiazepine, methamphetamine, and THC. The patient’s medications include a lorazepam taper for detoxification, clonidine as needed for detoxification and blood pressure, and promethazine as needed for nausea. Upon admission, the patient had a Clinical Institute Withdrawal Assessment for Alcohol (CIWA) score of 4 and a clinical opiate withdrawal scale (COWS) score of 6. He reported cravings.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: The patient has requested reimbursement for residential treatment center (RTC) services (ASAM 3.5). Per the American Society of Addiction Medicine (ASAM) criteria, this patient did not meet Level 3.5 criteria for RTC services. ASAM criteria focuses on six dimensions to determine the appropriate level of care, which includes: (1) intoxication and withdrawal potential; (2) biomedical conditions; (3) emotional, behavioral, and cognitive conditions; (4) readiness to change; (5) relapse, continued use, or continued problem potential; and (6) recovery environment.For dimension 1, the patient did not have any symptoms of withdrawal. Given these findings, the patient met ASAM 3.5 requirements for this dimension.For dimension 2, the patient presented to RTC with a lack of acute medical problems.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for residential treatment center (RTC) services. Several Psychiatric studies have unified and created a single instrument to determine the intensity of services needed. Per the study criteria, this patient did not meet Level 3.5 criteria for RTC services for the time period under review. The criteria focuses on six dimensions to determine the appropriate level of care, which includes: (1) intoxication and associated risk, withdrawal and associated risks, and addiction medication needs; (2) biomedical conditions including physical health concerns and pregnancy-related concerns; (3) psychiatric and cognitive conditions and history including active psychiatric symptoms and persistent disability; (4) substance use-related risks including the likelihood o…
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
How to use this in your appeal
These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for benzodiazepine use disorder was denied, the published record says the denial is worth fighting.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.